Allergic rhinitis (AR) is a global public health issue due to its high prevalence and its adverse impacts on sleep, cognitive functioning, mood, and associated comorbid conditions, such as asthma and sinusitis, and ultimately on quality of life and work and school performance. [1] [2] [3] A number of reviews have highlighted the socioeconomic burden of AR in terms of impaired work productivity, including lost work time (ie, absenteeism) and reduced performance while working (ie, impaired presenteeism). [4] [5] [6] [7] [8] Blanc et al 9 first reported that reduction in self-rated job effectiveness was more common in individuals with rhinitis (36%) than among those with asthma (19%), whereas absenteeism was similar in both conditions. US population-based surveys have provided estimates of the annual number of workdays missed because of AR ranging from 0.03 to 0.8 per employed individual. [10] [11] [12] [13] Goetzel et al 14 combined data on work productivity impairment from 3 large-scale US surveys and concluded that "allergy" (excluding asthma) was associated with an average 3.4% (range: 0.3% to 9.0%) productivity loss due to work absence and an average 10.9% (range: 8.3% to 14.5%) reduction in at-work performance. Even though an increasing number of studies of AR have included quantitative and validated measures of absenteeism and presenteeism, 15 to our knowledge, no systematic review (SR) of this area has yet been conducted. Therefore, available information on the impact of AR on work productivity remains fragmented and cannot be efficiently taken into account to guide clinical practice and public health interventions.
This SR aimed to synthesize and critically analyze the available information pertaining to the burden of AR on work productivity both in terms of absenteeism and impaired presenteeism to derive summary quantitative estimates of these effects. The secondary aim of this SR was to identify the factors that may affect, either negatively or positively, these productivity impairments.
METHODS Protocol
This SR was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (www.prismastatement.org). [and] rhinitis. Other databases were not searched, but we used the alternative strategy of sending the list of retrieved publications to an international panel of 11 experts in the field of allergy from 10 countries (Table E1 , available in this article's Online Repository at www.jaci-inpractice.org) asking them if they were aware of any other relevant published or unpublished data. In addition, the publications cited in the reference lists of the retrieved studies as well as review articles were carefully scrutinized to ensure that no original published data had been missed in the original search.
Selection of studies. The 41 retrieved papers were screened for eligibility by 2 independent reviewers (JB and OV) followed by full text evaluation of the 35 articles that met the initial inclusion criteria (see Figure E1 this article's Online Repository at www.jaciinpractice.org). Twelve studies were excluded because of methodological issues or missing data (Table E2 , available in this article's Online Repository at www.jaci-inpractice.org). This process left 23 remaining studies. The expert panel feedback identified 4 additional studies that were included in the analysis. [40] [41] [42] [43] Another 3 relevant publications were retrieved through the analysis of citations lists. [44] [45] [46] Data collection process. The data from the 30 included studies were extracted in a standardized manner and verified by 2 authors (OV and JB) using a list of predefined variables (Table E3 , available in this article's Online Repository at www.jaci-inpractice. org). The authors were contacted whenever possible to obtain additional information unavailable in the original publication. 30, 36, 41, 43 Assessment of the quality of selected studies. The studies were classified into 3 categories: (1) observational surveys; (2) interventional studies; and (3) economic evaluations of the impact of AR on work productivity. Bias in the observational surveys was evaluated using the Newcastle-Ottawa Quality scale for assessing the quality of cohort studies in meta-analyses (www.ohri.ca/programs/ clinical_epidemiology/oxford.htm). The risk of bias in randomized controlled trials (RCTs) was assessed using the descriptive Cochrane Collaboration's "Risk of bias" tool. 47 
Data analysis
Data of studies using the Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) instrument were pooled to estimate the magnitude of the work productivity impairment related to AR. The WPAI-AS was selected as the outcome measure for this pooled analysis because it has been extensively validated in a large variety of health disorders 15, 48, 49 (http://www.reillyassociates.net/ WPAI_References.html) and was the most commonly used instrument in the retrieved studies. The WPAI instrument produces 3 outcome measures of work disability: (1) the work time missed due to a specific health condition (ie, absenteeism); (2) the productivity impairment while working due to the specific health condition (ie, impaired presenteeism); and (3) the overall work impairment that is the sum of absenteeism and impaired presenteeism. 15, 48 These metrics are expressed as percentages (from 0% to 100%), with higher percentages indicating greater impairment. These were reported as noninteger summary values with a measure of variability for the distribution (eg, a mean and standard deviation [SD] or a median and interquartile range [IQR] ) that varied among the studies.
Baseline preintervention data that were reported separately by treatment versus control group in RCTs contributed separately to the pooled estimate, and, whenever relevant, stratified data by the pattern of AR (ie, seasonal/intermittent vs persistent) or disease severity (mild vs moderate-to-severe) also contributed separately to the overall pooled estimates.
For each WPAI metric (ie, absenteeism, presenteeism, and overall productivity impairment), the overall or subsets of pooled estimates of the mean value with its corresponding 95% confidence interval (95% CI) were calculated by weighting for the variance of each contributing value included in the estimate using a random effect approach, because heterogeneity among studies was high in all pooled estimated. Because individual studies could report either the standard error (SE), SD, or IQR, the sample variance of each reported metric was derived by applying the following formulae as appropriate:
, assuming normal distributions. Those sample variances were further transformed into the variances of the mean dividing by n, thus taking into account the size of the various studies.
Pooling was not possible for absenteeism in persistent and mild AR because only a single study/stratum was applicable. We also excluded from the pooled analyses data for the stratum of observations for the placebo group in 1 interventional study 31 because it reported an extreme variance estimate that could not be verified. Pooled analyses were performed with arithmetic calculations of spreadsheet-entered data in Excel. A pooled analysis of the effects of treatment interventions on work productivity could not be conducted because data were not collected using the WPAI-AS 32 or were not appropriately reported. 31, 33, [37] [38] [39] As a further approach to pooled estimates that did not presume a normal distribution of the mean values for absenteeism, presenteeism, or overall impaired productivity, we re-estimated these using a hierarchical modeling Bayesian meta-analytic approach. This allowed us to presume a Beta distribution for these data, given probabilities bounded between 0 and 1. Each outcome was modeled with 1 million draws using Stan software (http://mc-stan.org/).
RESULTS
The 30 selected studies included 19 observational surveys [17] [18] [19] [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] 40, 41, [43] [44] [45] [46] and 9 interventional studies. [31] [32] [33] [34] [35] [36] [37] [38] [39] Six studies reported economic evaluations, 18, 24, 32, [41] [42] [43] among which 3 were also identified among the observational surveys 18, 41, 43 and 1 among interventional studies. 32 
Characteristics of observational surveys
The surveyed populations, diagnostic criteria, and reported outcomes of the 19 observational surveys are summarized in Table I and Table E4 (available in this article's Online Repository at www.jaci-inpractice.org). The criteria and results of quality assessment are detailed in Table E5 (available in this article's Online Repository at www.jaci-inpractice.org). *Assessed using the Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) questionnaire.
Populations. The participants with AR were recruited from various population sources (Table E4 , available in this article's Online Repository at www.jaci-inpractice.org). Six studies compared AR individuals with referent groups without AR derived from the same population, 18, 21, 22, 25, 44, 46 but adjustment for confounding demographic characteristics and multimorbidity was performed in only 2 studies. 25, 46 Characteristics of AR. The diagnosis of AR was documented using various criteria as detailed in Table E4 (available in this article's Online Repository at www.jaci-inpractice.org). Ascertainment of allergen sensitization through skin-prick tests and/or serum-specific IgE antibodies was used as a diagnostic criterion in only 3 surveys 25, 40, 43 and reported to be present in 41% to 55% of the participants with AR in 3 other studies. 17, 19, 26 Five observational surveys provided the proportion of participants with moderate-to-severe AR (61% to 93%) (Table I) . 17, 21, 25, 30, 43 Work productivity was reported separately for mild and moderate-to-severe AR in only 2 studies. 17, 43 Eleven studies reported the duration of AR symptoms. 17, 22, 23, [26] [27] [28] [29] [30] 40, 43, 45 The proportion of persistent AR among these studies ranged from 0% to 72%. Data on work productivity were provided separately for persistent and intermittent AR in only 2 studies. 17, 43 Outcomes. Seven surveys collected data on the impact of AR on work productivity using validated instruments (Table I) : the WPAI instrument either in its specific version for allergic diseases (WPAI-AS) 17, 19, 30, 43 or in its generic version, 25 the Stanford Presenteeism Scale (SPS), 44 and the Work Productivity Short Inventory questionnaire. 18 The recall periods assessed by these questionnaires were 7 days, 4 weeks, and 12 months, respectively. In one prospective cohort study of participants with AR recruited in a random sample of specialized clinics in Spain, the WPAI-AS questionnaire was administered quarterly over a 1-year period. 43 The remaining observational surveys collected information on the impact of AR on work productivity using diverse nonvalidated instruments.
Characteristics of interventional studies Populations. Eight of the nine interventional studies (Table II   and Table E6 , available in this article's Online Repository at www.jaci-inpractice.org) were RCTs evaluating the effects of AR medications on work productivity. [31] [32] [33] [35] [36] [37] [38] [39] One study was a pragmatic, investigator-randomized design and compared the treatment of AR based on the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines with a "free-choice" strategy. 34 For 2 studies that failed to provide the number of enrolled participants who were currently employed, work and school productivity impairments could not be differentiated. 35, 36 Quality assessment of interventional studies is presented in Table E7 (available in this article's Online Repository at www.jaci-inpractice.org).
Characteristics of AR. Sensitization to relevant allergens
was ascertained in all participants with AR, although the tested allergens were not detailed in 4 studies. 33, 35, 36, 38 Five RCTs evaluated participants with "seasonal AR" 31, 33, 37, 39 and 1 RCT included participants with "intermittent AR." 35 Symptom severity at baseline was categorized according to a symptom score in 6 RCTs and to the ARIA grades in 1 study, 34 and was not specified in 1 study. 33 The majority (n ¼ 7) of the 9 RCTs enrolled participants with moderate-to-severe AR at baseline (Table E6 , available in this article's Online Repository at www. jaci-inpractice.org). 31, 32, [35] [36] [37] [38] [39] Outcomes. The impact of AR on work productivity was assessed using the WPAI-AS questionnaire in 8 RCTs (Table II) .
Absenteeism
Seven observational surveys reported that 3% to 30% of participants "missed work time due to AR," 22, 23, 26, 27, 29, 40, 45 but failed to provide any quantitative estimate of absenteeism (Table I) . Six observational surveys provided quantitative estimates of missed work time expressed as an absolute number of hours or days lost over variable intervals of time (Table I) . 18, 20, 21, 30, 41, 44 These estimates ranged from 0.8 to 9.9 workdays lost per year. The Medical Expenditure Panel Survey estimated a 0.6 incremental workday missed per year in participants with AR after controlling for sociodemographic characteristics, smoking, and multimorbidity. 46 The pooled analysis of 6 WPAI-based studies (1666 participants) provided an overall pooled estimate of 3.6% (95% CI, 2.4; 4.8%) missed work time due to AR (Table III) . 19, 25, 31, 37, 39, 43 The re-estimated pooled value using Bayesian modeling was 3.5% (95% CI, 2.6; 4.7%). Stratified by observational versus interventional design, the pooled estimates were 4.3% and 3.2%, respectively (Table III) . The pooled values for each stratum using Bayesian modeling were all within 0.1% of the original estimates (data not shown).
Presenteeism
Seven observational surveys reported that 10% to 50% of participants with AR experienced "work limitation" related to AR (Table II) . 22, 23, [26] [27] [28] 30, 45 Seven observational surveys assessed quantitatively the impact of AR on work productivity using various nonvalidated indices 18, 23, 26, 27, 29, 30, 41 (Table II) . The pooled analysis of impaired presenteeism included 8 studies using the WPAI-AS instrument (4563 participants) and provided an estimated 35.9% (95% CI, 29.7; 42.1%) impairment in work performance due to AR (Table III) . 17, 19, 25, 31, 34, 37, 39, 43 The re-estimated pooled value using Bayesian modeling was 35.8% (95% CI, 30.2; 41.7%). In stratified analyses, pooled estimates were higher for interventional versus observational studies (42.2% vs 28.6%); seasonal versus persistent AR (37.3% vs 28.0); and moderate-to-severe versus mild AR (38.1% vs 16.3%) ( Table III) . The differences between strata increased by a maximum of 0.4% substituting the estimates yielded through Bayesian modeling (data not shown).
Overall work productivity
The pooled analysis of 11 studies using the WPAI-AS questionnaire (6536 participants) found an estimated 39.4% (95% CI, 34.8; 44.0%) impairment in overall work productivity due to AR (Table III) . 17, 19, 25, 31, [33] [34] [35] [36] [37] 39, 43 The re-estimated pooled value using Bayesian modeling was 39.4% (95% CI, 35.1; 43.8%). Differences between strata were in the same direction and similar to those observed for impaired presenteeism, with the widest gap observed in overall work productivity being 24.9% comparing moderate-to-severe versus mild AR (Table III) . This gap was only slightly narrower (24.3%) using Bayesian estimates (data not shown).
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Comorbid ocular symptoms impacting work productivity
Two studies reported that ocular symptoms (conjunctivitis) in addition to nasal symptoms were associated with a more detrimental effect on work productivity 20 or "professional effectiveness." 22 One of these studies also documented an independent adverse effect of sleep disturbance and low health-related quality of life on work productivity. 20 
Impact of pharmacologic treatment
Overall, RCTs reported a beneficial effect of the pharmacologic treatment of AR on work productivity (Table IV) . 31, 39 One study showed that treatment based on ARIA guidelines significantly improved absenteeism and presenteeism as compared with a "free-choice" treatment. 34 Comparison with other health conditions A formal comparison of the work impairment due to AR with other chronic diseases could not be performed because the SR identified only 3 relevant surveys that used different outcome measures. Using the SPS, Collins et al 44 found that the mean work time missed (0.9 hour [95% CI: 0.7-1.1]) in the last 4 weeks and work performance impairment (18.2% [95% CI: 17.5-18.8%]) related to AR were similar to those attributed to asthma, arthritis, diabetes, heart and circulatory problems, and musculoskeletal disorders. Lamb et al 18 reported that the estimated mean total productivity loss per employee during the last year, including the number of days missed and the number of unproductive hours, was significantly higher for AR compared with 10 other chronic conditions, including high stress, migraine, depression, arthritis/rheumatism, anxiety disorders, respiratory infections, hypertension, diabetes, asthma, and coronary heart disease. Using the generic WPAI, de la Hoz et al 25 found that absenteeism was similar in AR (adjusted mean AE SE, 4.6 AE 1.1%) compared with diabetes (4.2 AE 1.7%) and hypertension (2.1 AE 1.5%) but significantly lower than in symptomatic depression (31.7 AE 2.6%). AR was associated with a significantly higher overall loss of productivity (adjusted mean AE SE, 26.6 AE 1.8%) than hypertension (8.8 AE 2.5%) and diabetes (16.7 AE 2.8%), but it was lower than in symptomatic depression (59.5 AE 4.3%).
Economic evaluations
Six studies assessed the economic costs of lost work productivity related to AR (Table V) . 18, 24, 32, [41] [42] [43] Overall, these economic evaluations indicated that the costs of impaired presenteeism were 2.2-to 18.7-fold higher than those of absenteeism, whereas the total costs of lost productivity (ie, absenteeism plus impaired presenteeism) were 3.2-to 13.5-fold higher than the direct medical costs. The indirect costs resulting from lost work productivity represented 76% to 93% of the total AR costs.
A Swedish population-based questionnaire survey 42 showed that the cost of moderate-to-severe persistent AR was 4-fold higher than mild persistent AR. A prospective 1-year cohort study found that the mean indirect costs resulting from presenteeism were approximately 1.9-fold higher in moderate-tosevere AR compared with mild AR and 2.3-fold higher in participants with persistent AR compared with those with intermittent AR. 43 The cost of absenteeism did not differ according to the severity or duration of AR symptoms. In persistent *National average of workers' daily wage used by investigators to calculate the cost components of AR. †Cost of presenteeism/cost of absenteeism ratio. zTotal cost of lost productivity/direct medical cost ratio.
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DISCUSSION

Summary of evidence
The pooled analysis of WPAI-based studies identified in this SR showed that AR is associated with a substantial adverse impact on the productivity at work (ie, presenteeism) with an estimated 35.9% (95% CI, 29.7; 42.1%) impairment, whereas the impact on absenteeism was minimal (3.6% [95% CI, 2.4; 4.8%]). These figures are similar to previous estimates of absenteeism, whereas estimates of impaired productivity at work are higher than those reported in previous US surveys that used various instruments to quantify the impact of AR on work productivity. [10] [11] [12] [13] [14] The estimates derived in this SR are however in line with those reported by 2 recently published WPAI-based studies conducted in Asian health care settings that documented mean (SD) overall productivity impairment due to AR of 32% (26%) and 40% (29%). 50, 51 Overall, this SR indicated that the level of impaired productivity due to AR is at least similar to that reported in many other chronic diseases. 18, 25, 44 The recent Asian studies cited previously further confirm that overall work productivity is more impaired by rhinitis than asthma (33 [30] 49 However, in this SR, the studies on asthma and "allergies" were pooled together and included only 2 studies on rhinitis. 17, 48 Nevertheless, the impact of seasonal or intermittent AR is likely to be of more limited duration than other chronic diseases.
This SR confirmed that more severe AR is associated with a more detrimental impact on work productivity, 17, 19, 21, 22, 25, 30, 41, 43 with a substantial difference of 24.9% and nonoverlapping 95% CIs between the pooled estimates of moderate-to-severe versus mild disease. These findings are further substantiated by a recent study showing a correlation between the WPAI-AS score and the overall intensity of AR symptoms assessed using a visual analog scale. 52 In addition, this SR indicated that associated conjunctivitis and sleep disturbances could have a detrimental effect on work productivity independently from nasal symptoms. 20, 22 The aggravating role of ocular symptoms was further substantiated by an observational survey of patients with AR recruited by primary care physicians and specialists that, however, was not eligible for inclusion in this SR because detailed WPAI questionnaire data were not reported. 53 This study demonstrated that ocular symptoms were associated with a greater impact on absenteeism and productivity while at work, even after adjustment for the severity of nasal symptoms. A number of observational surveys in this SR reported on sleep problems related to AR, 17, [19] [20] [21] 23, 26, 27, 40, 45 but they failed to investigate the specific impact of sleep disorders on work productivity, with the exception of the study by Szeinbach et al. 20 These findings-if further confirmed-may have clinical implications because ocular symptoms and sleep disturbances are highly prevalent among patients with AR and are often underestimated by health care providers. 1, 54, 55 Greater awareness of these symptoms and their potential effects may help physicians to identify subjects with an increased risk of impaired work productivity and to target their treatment to reduce the work and economic impact of AR.
Although a formal meta-analysis of the effects of the pharmacological treatment of AR was not appropriate to the data available, the RCTs identified through this SR showed an overall beneficial effect of oral antihistamines and nasal sprays on work productivity. These findings are in line with a critical review of studies published before 2003 showing that treatment with nonsedating antihistamines reduces the productivity losses due to AR. 56 Earlier population-based studies conducted in the USA provided a wide range of estimates of the indirect costs of AR, ranging from 7% 11 to 25% 10 of the total costs. Unfortunately, few studies have assessed both absenteeism and presenteeism. 6 The current SR indicates that: (1) the indirect costs associated with lost work productivity are the principal component of the total AR costs and result mainly from the costs of presenteeism and (2) the indirect costs of AR appear to be greater than or similar to those resulting from many other chronic diseases traditionally considered as being more important from a medical perspective.
Limitations
Methodological weaknesses of this SR should be considered for interpreting its estimates of the burden of AR on work productivity. First, the pooled estimates of the impact of AR on work productivity were derived from a limited number of studies based on the validated WPAI instrument. These studies were heterogeneous in their findings that we addressed by relying on random effect modeling for pooled estimates. Moreover, additional analyses using a Bayesian approach stipulating a Beta rather than normal distribution of mean values yielded pooled estimates that were not substantially different from a standard meta-analytic approach. Many observational surveys used nonvalidated measures of at-work productivity. For example, most reports of the effects of pharmacological interventions presented data in a form that could not be utilized in a pooled analysis. The findings from these non-WPAI studies were only descriptively assessed and summarized.
Second, IgE sensitization to aeroallergens was not systematically documented in the majority of observational surveys. Thus, the findings derived from these surveys are likely to be relevant not only to AR, but also to other forms of rhinitis.
Third, most available studies had a substantial, although unquantifiable, potential for bias toward the selection of participants with more severe AR. The subjects with AR participating in population or patient panels [21] [22] [23] [26] [27] [28] [29] [30] 41 and "convenience" samples surveys 18, 45 might be those who were more prone to report a higher impact of the disease. Individuals who seek primary health care 17, 19, 25, 40, 43 or managed care 20 are unlikely to accurately represent the whole population of individuals suffering from AR. Only 5 of the 19 observational surveys provided information on the severity of AR, 17, 21, 25, 30, 43 and data on work productivity impairment associated with mild AR were available in only 2 studies. 17, 43 Moderate-to-severe AR seemed to be overrepresented in observational surveys as compared with existing population-based data (eg, 29% to 40% 54, 57 ); the proportion of participants with moderate-to-severe AR ranged from 61% to 93% in the 5 surveys that provided this information. 17, 21, 25, 30, 43 In addition, RCTs are inherently affected by a selection bias toward more severe and/or symptomatic AR because, in these studies, only participants with a moderate-to-severe disease were enrolled. This may explain why the pooled estimates of overall productivity (Table III) were higher for interventional compared with observational studies, underscoring that differences in study design, including subject selection, can effect disability estimates despite using the same WPAI instrument.
Beyond these limitations, studies based on self-reporting may be affected by recall failure and attribution bias (eg, confusion about whether AR is the cause of the work impairment). Few available studies attempted to disentangle the impact of AR from that resulting from comorbid conditions, particularly asthma and rhinosinusitis, although these conditions may increase the adverse impact on work productivity. 58, 59 Only 2 observational surveys took into account the potential confounding demographic characteristics and comorbidities in the analysis of their results. 25, 46 Another major limitation derives from the fact that the impact of seasonal AR cannot be estimated on an annual time framework. The WPAI-AS questionnaire is one of the best validated tools to assess absenteeism and presenteeism in AR. 15, 48 The WPAI-AS questionnaire is applied for a 7-day recall period in an attempt at minimizing the recall bias. However, most studies evaluating specifically individuals with seasonal AR were interventional studies based on the WPAI-AS that were conducted during the relevant pollen season and failed to provide information on the total duration of the symptomatic period, 31, 33, 37, 39 whereas work impairment has been significantly correlated with outdoor pollen and mold levels in individuals with AR. 60, 61 Apps running on smartphone devices can help gather real-time information on daily work performance and AR symptoms over longer periods of time and, accordingly, should further reduce recall bias and make it possible to estimate more accurately the cumulative impact of seasonal and intermittent AR on work productivity. 62 
CONCLUSIONS
This SR indicates that AR is substantially impairing at-work productivity (presenteeism) but only minimally absenteeism, although further studies assessing daily work productivity and severity of symptoms at the same time over prolonged periods and comparing with other chronic diseases are needed to better characterize the impact of AR. Nevertheless, the findings of this SR should increase the awareness of the medical community on the impact of AR on work productivity and provide an evidencebase to assist health care payers and policy makers implementing interventions to reduce the socioeconomic burden of AR.
ONLINE REPOSITORY FIGURE E1. Flowchart of the retrieval and selection of included studies. The 6 economic evaluations of the impact of allergic rhinitis on work productivity included 3 studies that were also considered in observational surveys and one in interventional studies. Cost-of-illness study of 1137 patients with AR treated with homeopathy compared with control patients without homeopathy among a German health insurance company Lack of detailed data on work productivity specific to AR AR, Allergic rhinitis; GP, general practitioner; WPAI-AS, Work Productivity and Activity Impairment questionnaire-Allergy Specific. AR, Allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; HDM, house dust mite; IAR, intermittent AR; PAR, persistent AR; RCT, randomized controlled trial; SAR, seasonal AR; SPT, skin-prick test; Sx, symptoms; T4SS, total four symptoms score; T5SS, total five symptoms score; TNSS, sum of individual nasal symptoms (obstruction/ blockage/congestion, drainage [anterior/posterior], nasal itch, and sneezing) rated on a 0-6 severity scale. *Adapted ARIA guidelines: ebastine 10 mg OD in mild IAR; ebastine 10 mg OD in mild PAR; ebastine 10 mg BID in moderate/severe IAR; ebastine 10 mg BID and intranasal corticosteroid in moderate/severe PAR. †Moderate/severe AR defined as a !50-mm visual analog score. zUnknown working status. Selection of moderate/severe AR Exclusion of asthma requiring maintenance treatment AR, Allergic rhinitis; AHI, apnea-hypopnea index; D-B, double-blinded study; H, high risk of bias; L, low risk of bias; ND, not detailed; P-C, placebo-controlled study; U, uncertain risk of bias. Adapted from the Cochrane Collaboration's "risk of bias" tool (available from: www.handbook.cochrane.org). *Lack of detailed information on the blinding procedures for outcome assessment (ie, work productivity), but the outcome measurement is unlikely to be influenced because it was performed using a validated self-completed questionnaire (ie, Work Productivity and Activity Impairment questionnaire).
